Catalyst Pharmaceuticals (CPRX) Interest & Investment Income (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Interest & Investment Income came in at $8000.0 in Q1 2026, up 109.88% YoY from $3811.8 in Q1 2025, and up 125.81% on a QoQ basis from -$31000.0 in Q3 2025.
Powered by 
Analysis
Catalyst Pharmaceuticals (CPRX) Interest & Investment Income (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 14 years of Interest & Investment Income data on file, last reported at $8000.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 109.88% year-over-year to $8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25000.0 (up 247.06% YoY) and the FY2025 annual result came in at -$64000.0, down 228.0% from the prior year.
- Interest & Investment Income grew to $8000.0 in Q1 2026, from -$31000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $323000.0 in Q2 2022 to a low of -$305000.0 in Q1 2022.
- A 5-year average of $11142.9 and a median of -$2500.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 6500.0% — and 2025, when it slumped 478.57%.
- Tracing CPRX's Interest & Investment Income over 5 years: stood at -$8000.0 in 2022, then surged by 87.5% to -$1000.0 in 2023, then soared by 6500.0% to $64000.0 in 2024, then plunged by 148.44% to -$31000.0 in 2025, then soared by 125.81% to $8000.0 in 2026.
- The last three Interest & Investment Income figures came in at $8000.0 (Q1 2026), -$31000.0 (Q3 2025), and $48000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 8,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Sep 30, 2025 | -31,000.00 |
| Jun 30, 2025 | 48,000.00 |
| Mar 31, 2025 | -81,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | -13,000.00 |
| Dec 31, 2022 | -8,000.00 |
| Sep 30, 2022 | 162,000.00 |
| Jun 30, 2022 | 323,000.00 |
| Mar 31, 2022 | -305,000.00 |
| Dec 31, 2021 | -85,000.00 |
| Sep 30, 2021 | -26,000.00 |
| Jun 30, 2021 | 8,000.00 |
| Mar 31, 2021 | -76,000.00 |
| Dec 31, 2020 | 38,000.00 |
| Sep 30, 2020 | -5,000.00 |